Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Laboratory of Neuro-Oncology, Clinical and Cancer Proteomics, Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Mult Scler. 2023 Jan;29(1):52-62. doi: 10.1177/13524585221125369. Epub 2022 Sep 24.
Pediatric-onset multiple sclerosis (POMS) represents the earliest stage of disease pathogenesis. Investigating the cerebrospinal fluid (CSF) proteome in POMS may provide novel insights into early MS processes.
To analyze CSF obtained from children at time of initial central nervous system (CNS) acquired demyelinating syndrome (ADS), to compare CSF proteome of those subsequently ascertained as having POMS versus monophasic acquired demyelinating syndrome (mADS).
Patients were selected from two prospective pediatric ADS studies. Liquid chromatography-mass spectrometry (LC-MS) was performed in a Dutch discovery cohort (POMS = 28; mADS = 39). Parallel reaction monitoring-mass spectrometry (PRM-MS) was performed on selected proteins more abundant in POMS in a combined Dutch and Canadian validation cohort (POMS = 48; mADS = 106).
Discovery identified 5580 peptides belonging to 576 proteins; 58 proteins were differentially abundant with ⩾2 peptides between POMS and mADS, of which 28 more abundant in POMS. Fourteen had increased abundance in POMS with ⩾8 unique peptides. Five selected proteins were all confirmed within validation. Adjusted for age, 2 out of 5 proteins remained more abundant in POMS, that is, and .
This exploratory study identified several CSF proteins associated with POMS and not mADS, potentially reflecting neurodegeneration, compensatory neuroprotection, and humoral response in POMS. The proteins associated with POMS highly correlated with age at CSF sampling.
儿科发病多发性硬化症(POMS)代表疾病发病机制的最早阶段。研究 POMS 患者的脑脊液(CSF)蛋白质组可能为早期 MS 进程提供新的见解。
分析初诊时发生中枢神经系统(CNS)获得性脱髓鞘综合征(ADS)的儿童的 CSF,比较随后确定为 POMS 与单相获得性脱髓鞘综合征(mADS)的 CSF 蛋白质组。
从两项前瞻性儿科 ADS 研究中选择患者。在荷兰发现队列中进行液相色谱-质谱(LC-MS)(POMS = 28;mADS = 39)。在荷兰和加拿大联合验证队列中,对 POMS 中更丰富的选定蛋白质进行平行反应监测-质谱(PRM-MS)(POMS = 48;mADS = 106)。
发现鉴定出 5580 种肽段,属于 576 种蛋白质;58 种蛋白质在 POMS 和 mADS 之间有 ⩾2 种肽段差异丰富,其中 28 种在 POMS 中更丰富。在 POMS 中有 ⩾8 种独特肽段的 14 种蛋白表达增加。在验证中,5 种选定的蛋白质均得到确认。调整年龄后,5 种蛋白质中有 2 种在 POMS 中仍然更丰富,即 和 。
这项探索性研究确定了几种与 POMS 而非 mADS 相关的 CSF 蛋白,可能反映了 POMS 中的神经退行性变、代偿性神经保护和体液反应。与 POMS 相关的蛋白与 CSF 采样时的年龄高度相关。